AHF Praises Merck for AIDS Drug Price Freeze in US

AIDS Healthcare Foundation (AHF) the US-based NGO which provides HIV/AIDS medical care and/or services to more than 79,000 individuals in 20 countries worldwide–including at four free treatment clinics in Mexico–lauded Merck & Company over it intention to freeze the price on its second-line antiretroviral AIDS drug therapy Isentress (raltegravir) for US government programs such as the federally funded, state-run AIDS Drug Assistance Programs (ADAP). Merck, which announced its intentions in a press statement last week, will freeze the price of Isentress at its 2007 launch price.

“Merck’s decision to freeze the price of Isentress at its 2007 launch price for government programs and the open market in the US is to be commended,” said Michael Weinstein, AIDS Healthcare Foundation President. “With the US economy in a downward spiral and many states facing huge budget deficits, Merck’s action last week will help many state ADAPs be able to continue to provide lifesaving AIDS drugs–particularly, more expensive second-line treatments, to poorer people in need through the US. While we laud Merk for this action, we will continue to press both government agencies and private industry for lower drug pricing to increase access to antiretroviral treatment both in the US and globally.”

About AHF

AIDS Healthcare Foundation (AHF) is the US’ largest HIV/AIDS organization. AHF currently provides treatment, care and support services to more than 79,000 individuals in 20 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at www.aidshealth.org